Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Fosaprepitant→

Fosaprepitant Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
172673-20-0
Molecular formula
C23H22F7N4O6P
Molecular weight
614.4 g/mol
Drug class
Neurokinin-1 (NK1) receptor antagonist prodrugantiemetic
Mechanism of action
Fosaprepitant is converted to aprepitant, which selectively antagonises substance P at NK1 receptors in the central nervous system and gastrointestinal pathways involved in emesis.
Indications / reported uses
  • Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin-based regimens, in combination with other antiemetics
  • Prevention of nausea and vomiting associated with moderately emetogenic chemotherapy where covered by the specific product regimen

Sources: US DailyMed — EMEND for Injection (fosaprepitant) · NLM MeSH — Fosaprepitant · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Neurokinin-1 (NK1) receptor antagonist prodrug; antiemetic

Mechanism of action

Fosaprepitant is converted to aprepitant, which selectively antagonises substance P at NK1 receptors in the central nervous system and gastrointestinal pathways involved in emesis.

General use cases

  • Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin-based regimens, in combination with other antiemetics
  • Prevention of nausea and vomiting associated with moderately emetogenic chemotherapy where covered by the specific product regimen

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Fosaprepitant Environmental Risk Assessment (ERA) (the Fosaprepitant ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.